article thumbnail

Study finds new therapeutic targets for neurodegenerative disease

Drug Discovery World

AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). By working with Insilico Medicine, we have provided a roadmap for researchers to navigate this complex terrain.”

Protein 69
article thumbnail

Start-up hopes to boost production of viral vectors for ATMPs

Drug Discovery World

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Insilico Medicine gets $255 million to boost AI-powered R&D, announces a collaboration

Scienmag

Credit: Insilco June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into (..)

article thumbnail

Drug discovery’s senior appointments for Q4

Drug Discovery World

Kimryn Rathmell has been chosen as the 17 th director of the National Cancer Institute (NCI), bringing her experience as leader of the Department of Medicine at the Vanderbilt University Medical Center and Physician-in-Chief at the Vanderbilt University Adult Hospital and Clinics.

Drugs 52
article thumbnail

Saarbrücken based bioinformaticians trace down molecular signals of Parkinson’s disease

Scienmag

For their study, the team led by bioinformatics professor Andreas Keller and his doctoral student […]. Credit: Oliver Dietze In their study, which is now published in the journal Nature Aging, they show that the level of non-coding RNAs in the blood of a Parkinson’s patient can be used to track the course of the disease.

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine,” said Marc Casper, Chairman, President and Chief Executive Officer of Thermo Fisher.

Drugs 52
article thumbnail

Jafri conducting study of in silico prediction of cancer drug susceptibility

Scienmag

Mohsin Jafri, Director, Neuroscience Program; Professor Bioinformatics/Computational Biology, is studying cancer drug susceptibility. This technology may be applied to data extracted from the molecular […].